What's behind GSK's massive earnings and will the stock price surge continue?

Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance, driven by long-overdue regulatory relief, including significant price hikes in 2023–2024.

This shift came after years of capped prices, surging API costs, and currency depreciation that had severely squeezed margins.

GSK Pakistan, in particular, posted dramatic earnings rebound — from PKR 534 million in 2023 to over PKR 6.5 billion in 2024 — led by improved pricing and margin expansion.

Watch the full video for a comprehensive pharma industry analysis and stock analysis of GSK.